The Filings Report

Alnylam Pharmaceuticals, Inc.

ALNYNasdaqCIK 1178670Healthcare / Drug Manufacturersfiscal year ends December70 quarters since 2009

Revenue, Q3 FY2026
$1.5B
+16.7% on Q3 FY2025
Net income
$2.2B
+640.5% on Q3 FY2025
Free cash flow
$271M
−4.8% on Q3 FY2025
Diluted EPS
$15.72
+634.6% on Q3 FY2025
Revenue, TTM
—
trailing four quarters
Net margin, TTM
—
net income $2.6B
Free cash flow, TTM
—
Cash and equivalents
$1.8B
long-term debt —, Sep 30, 2026
Shares, 12-month change
+1.4%
134M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$22.1B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Alnylam Pharmaceuticals, Inc. reported revenue of $1.5B, +16.7% on Q3 FY2025, and net income of $2.2B (+640.5%). Operating margin was 23.7%. Free cash flow, operating cash flow less capital expenditures, was $271M ($341M less $70M). Diluted earnings per share were $15.72.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$1B$0$1B$2B$3BQ4'22, Revenue: $335MQ4'22, Net income: −$207MQ4'22Q1'23, Revenue: $319MQ1'23, Net income: −$174MQ1'23Q2'23, Revenue: $319MQ2'23, Net income: −$276MQ2'23Q3'23, Revenue: $751MQ3'23, Net income: $148MQ3'23Q4'23, Revenue: $440MQ4'23, Net income: −$138MQ4'23Q1'24, Revenue: $494MQ1'24, Net income: −$66MQ1'24Q2'24, Revenue: $660MQ2'24, Net income: −$17MQ2'24Q3'24, Revenue: $501MQ3'24, Net income: −$112MQ3'24Q4'24, Revenue: $593MQ4'24, Net income: −$84MQ4'24Q1'25, Revenue: $594MQ1'25, Net income: −$18MQ1'25Q2'25, Revenue: $774MQ2'25, Net income: −$72MQ2'25Q3'25, Revenue: $1.2BQ3'25, Net income: $293MQ3'25Q4'25, Revenue: $1.1BQ4'25, Net income: $112MQ4'25Q1'26, Net income: $206MQ1'26Q2'26, Revenue: $1.3BQ2'26, Net income: $164MQ2'26Q3'26, Revenue: $1.5BQ3'26, Net income: $2.2BQ3'26−$1B$0$1B$2B$3BQ4'22, Revenue: $335MQ4'22, Net income: −$207MQ1'23, Revenue: $319MQ1'23, Net income: −$174MQ1'23Q2'23, Revenue: $319MQ2'23, Net income: −$276MQ3'23, Revenue: $751MQ3'23, Net income: $148MQ3'23Q4'23, Revenue: $440MQ4'23, Net income: −$138MQ1'24, Revenue: $494MQ1'24, Net income: −$66MQ1'24Q2'24, Revenue: $660MQ2'24, Net income: −$17MQ3'24, Revenue: $501MQ3'24, Net income: −$112MQ3'24Q4'24, Revenue: $593MQ4'24, Net income: −$84MQ1'25, Revenue: $594MQ1'25, Net income: −$18MQ1'25Q2'25, Revenue: $774MQ2'25, Net income: −$72MQ3'25, Revenue: $1.2BQ3'25, Net income: $293MQ3'25Q4'25, Revenue: $1.1BQ4'25, Net income: $112MQ1'26, Net income: $206MQ1'26Q2'26, Revenue: $1.3BQ2'26, Net income: $164MQ3'26, Revenue: $1.5BQ3'26, Net income: $2.2BQ3'26

Net income losses drawn in red.

Free cash flow
−$200M$0$200M$400MQ4'22, Free cash flow: −$154MQ4'22Q1'23, Free cash flow: −$180MQ1'23Q2'23, Free cash flow: −$75MQ2'23Q3'23, Free cash flow: $342MQ3'23Q4'23, Free cash flow: −$45MQ4'23Q1'24, Free cash flow: −$94MQ1'24Q2'24, Free cash flow: $116MQ2'24Q3'24, Free cash flow: $40MQ3'24Q4'24, Free cash flow: −$104MQ4'24Q1'25, Free cash flow: −$127MQ1'25Q2'25, Free cash flow: $114MQ2'25Q3'25, Free cash flow: $285MQ3'25Q4'25, Free cash flow: $194MQ4'25Q1'26Q2'26Q3'26, Free cash flow: $271MQ3'26−$200M$0$200M$400MQ4'22, Free cash flow: −$154MQ1'23, Free cash flow: −$180MQ1'23Q2'23, Free cash flow: −$75MQ3'23, Free cash flow: $342MQ3'23Q4'23, Free cash flow: −$45MQ1'24, Free cash flow: −$94MQ1'24Q2'24, Free cash flow: $116MQ3'24, Free cash flow: $40MQ3'24Q4'24, Free cash flow: −$104MQ1'25, Free cash flow: −$127MQ1'25Q2'25, Free cash flow: $114MQ3'25, Free cash flow: $285MQ3'25Q4'25, Free cash flow: $194MQ1'26Q3'26, Free cash flow: $271MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$500M$1.0B$1.5B$2.0BQ4'22, Cash and equivalents: $866MQ4'22Q1'23, Cash and equivalents: $672MQ1'23Q2'23, Cash and equivalents: $658MQ2'23Q3'23, Cash and equivalents: $1.0BQ3'23Q4'23, Cash and equivalents: $813MQ4'23Q1'24, Cash and equivalents: $682MQ1'24Q2'24, Cash and equivalents: $968MQ2'24Q3'24, Cash and equivalents: $1.1BQ3'24Q4'24, Cash and equivalents: $966MQ4'24Q1'25, Cash and equivalents: $1.0BQ1'25Q2'25, Cash and equivalents: $1.1BQ2'25Q3'25, Cash and equivalents: $1.5BQ3'25Q4'25, Cash and equivalents: $1.7BQ4'25Q1'26Q2'26, Cash and equivalents: $1.7BQ2'26Q3'26, Cash and equivalents: $1.8BQ3'26$0$500M$1.0B$1.5B$2.0BQ4'22, Cash and equivalents: $866MQ1'23, Cash and equivalents: $672MQ1'23Q2'23, Cash and equivalents: $658MQ3'23, Cash and equivalents: $1.0BQ3'23Q4'23, Cash and equivalents: $813MQ1'24, Cash and equivalents: $682MQ1'24Q2'24, Cash and equivalents: $968MQ3'24, Cash and equivalents: $1.1BQ3'24Q4'24, Cash and equivalents: $966MQ1'25, Cash and equivalents: $1.0BQ1'25Q2'25, Cash and equivalents: $1.1BQ3'25, Cash and equivalents: $1.5BQ3'25Q4'25, Cash and equivalents: $1.7BQ1'26Q2'26, Cash and equivalents: $1.7BQ3'26, Cash and equivalents: $1.8BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Alnylam Pharmaceuticals, Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Jul 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue1,4581,291—1,0971,249774594593+16.7%
Cost of revenue362298—26819714270103+83.4%
Gross profit—————————
Research and development409413—372359324265300+13.9%
Selling, general and administrative342348—325322323240295+6.2%
Operating income346231—132368(16)18(105)−6.0%
Other income (expense)(50)(54)—(45)(87)(25)(20)(89)+42.8%
Pretax income296178—86281(41)(2)(194)+5.4%
Income tax(1,872)13—(25)(12)3116(110)−15348.0%
Net income2,167164206112293(72)(18)(84)+640.5%
Diluted EPS ($)15.721.21——2.14(0.55)(0.14)—+634.6%
Diluted shares (millions)138138——137131130——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Alnylam Pharmaceuticals, Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Jul 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents1,7541,708—1,6571,4901,1141,020966+17.7%
Short-term investments1,8331,600—1,2511,2341,7441,6051,720+48.5%
Total current assets5,1134,620—4,0513,9533,6443,2683,295+29.3%
Total assets7,9955,559—4,9664,8524,5664,2144,240+64.8%
Total current liabilities2,0631,513—1,4661,5551,3011,0761,186+32.6%
Long-term debt—————————
Total liabilities4,3914,205—4,1774,6184,3154,0984,173−4.9%
Stockholders’ equity3,6041,3541,07578958055542667+521.1%
Shares outstanding (millions)134134134133132131130129—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Alnylam Pharmaceuticals, Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Jul 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow341——218297128(118)(95)+14.9%
Capital expenditures70——23121499+475.1%
Free cash flow (CFO − capex)271——194285114(127)(104)−4.8%
Depreciation and amortization14——1414141414+4.9%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 12, 2026.

Income statement

Alnylam Pharmaceuticals, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 10, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 14, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 15, 2017FY2015ended Dec 31, 2015filed Feb 12, 2016FY2014ended Dec 31, 2014filed Feb 13, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 19, 2013FY2011ended Dec 31, 2011filed Feb 13, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Aug 5, 2010FY2008ended Dec 31, 2008filed Aug 5, 2010
Revenue3,7142,2481,8281,037844493220759047—————10010196
Cost of revenue677307268140115742520—————————
Gross profit——————————————————
Research and development1,3201,1261,004883792655655505391382276190113879910610997
Selling, general and administrative1,211976796771621588479382199896145274538384027
Operating income502(177)(282)(785)(709)(828)(939)(815)(500)(425)(296)(405)(93)(129)(55)(44)(48)(28)
Other income (expense)(178)(200)(151)(342)(143)(27)545491464113(3)112
Pretax income323(377)(434)(1,127)(852)(856)(885)(761)(491)(410)(290)(401)(92)(117)(58)(43)(47)(26)
Income tax9(99)741311000(40)(3)(11)0111
Net income314(278)(440)(1,131)(853)(858)(886)(761)(491)(410)(290)(360)(89)(106)(58)(44)(48)(26)
Diluted EPS ($)2.33(2.18)(3.52)(9.30)(7.20)(7.46)(8.11)———————————
Diluted shares (millions)135128125122118115109———————————

Balance sheet

Alnylam Pharmaceuticals, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 10, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 14, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 15, 2017FY2015ended Dec 31, 2015filed Feb 12, 2016FY2014ended Dec 31, 2014filed Feb 13, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 19, 2013FY2011ended Dec 31, 2011filed Feb 13, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Aug 5, 2010FY2008ended Dec 31, 2008filed Aug 5, 2010
Cash and equivalents1,6579668138668204975474206451941817553517075137192
Short-term investments1,2511,7201,6161,2981,5491,3339756631,0454248485271937176159144—
Total current assets4,0513,2952,9832,6922,8092,6151,7161,2011,7656721,105746254126152254294—
Total assets4,9664,2403,8303,5463,6433,4072,3951,5751,9951,2631,3871,080421288282393481—
Total current liabilities1,4661,1869687686965853531791441326295544881102111—
Long-term debt————676191————————————
Total liabilities4,1774,1734,0513,7053,0552,391956273228343122143150153164235303—
Stockholders’ equity78967(221)(158)5881,0161,4391,3021,7669201,265936270134118158178202
Shares outstanding (millions)13312912612412011711310610086858464624342——

Cash flow statement

Alnylam Pharmaceuticals, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 10, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 14, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 15, 2017FY2015ended Dec 31, 2015filed Feb 12, 2016FY2014ended Dec 31, 2014filed Feb 13, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 19, 2013FY2011ended Dec 31, 2011filed Feb 13, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Aug 5, 2010FY2008ended Dec 31, 2008filed Aug 5, 2010
Operating cash flow524(8)104(541)(642)(615)(278)(563)(383)(308)——(69)(116)(87)(84)(72)65
Capital expenditures593462727670140127104651394815511
Free cash flow (CFO − capex)465(43)42(613)(718)(685)(419)(690)(487)(372)——(73)(124)(88)(89)(77)55
Depreciation and amortization5657544448351715121519121095566
Share repurchases——————————————————
Dividends paid——————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$399K
1 sales by 1 insider; officers and directors $399K
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$44M
279 sales by 8 insiders; officers and directors $44M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 2, 2026Supran BryanEVP, CLO and Secretaryopen-market sale1,758$226.88$399K12,807Oct 6, 2026
Sep 19, 2026Greenstreet YvonneChief Executive Officer, Directoraward107$0.00—95,802Sep 22, 2026
Jun 1, 2026Pyott David E IDirectoroption exercise3,830$0.00—5,412Jun 3, 2026
Jun 1, 2026Pyott David E IDirectoropen-market sale10b5-1921$297.71$274K4,491Jun 3, 2026
Jun 1, 2026Pyott David E IDirectoropen-market sale10b5-11,175$298.91$351K3,316Jun 3, 2026
Jun 1, 2026Pyott David E IDirectoropen-market sale10b5-11,222$299.87$366K2,094Jun 3, 2026
Jun 1, 2026Pyott David E IDirectoropen-market sale10b5-1495$300.72$149K1,599Jun 3, 2026
Jun 1, 2026Pyott David E IDirectoropen-market sale10b5-117$302.65$5K1,582Jun 3, 2026
May 20, 2026Sigal Charles ElliottDirectoraward671$0.00—1,446May 22, 2026
May 20, 2026Schulman Amy WDirectoraward838$0.00—24,049May 22, 2026
May 20, 2026Reitan Colleen FDirectoraward671$0.00—1,446May 22, 2026
May 20, 2026Pyott David E IDirectoraward671$0.00—1,582May 22, 2026
May 20, 2026Kellogg Peter NDirectoraward671$0.00—1,446May 22, 2026
May 20, 2026Hamburg Margaret ADirectoraward671$0.00—1,582May 22, 2026
May 20, 2026Brandicourt OlivierDirectoraward671$0.00—1,446May 22, 2026
May 20, 2026Ausiello Dennis ADirectoraward671$0.00—1,582May 22, 2026
May 20, 2026Arbuckle Stuart ADirectoraward671$0.00—671May 22, 2026
May 13, 2026Schulman Amy WDirectoroption exercise11,250$70.20$790K23,211May 14, 2026
Apr 6, 2026McLaughlin MelissaChief Human Resources Officeropen-market sale10b5-156$320.14$18K11,673Apr 7, 2026
Apr 6, 2026McLaughlin MelissaChief Human Resources Officeropen-market sale10b5-1909$329.76$300K10,764Apr 7, 2026
Apr 6, 2026McLaughlin MelissaChief Human Resources Officeropen-market sale10b5-1829$330.46$274K9,935Apr 7, 2026
Apr 6, 2026McLaughlin MelissaChief Human Resources Officeropen-market sale10b5-1293$331.89$97K9,642Apr 7, 2026
Apr 6, 2026McLaughlin MelissaChief Human Resources Officeropen-market sale10b5-1199$333.94$66K9,443Apr 7, 2026
Apr 2, 2026McLaughlin MelissaChief Human Resources Officeropen-market sale10b5-1265$316.61$84K13,088Apr 7, 2026
Apr 2, 2026McLaughlin MelissaChief Human Resources Officeropen-market sale10b5-1359$317.44$114K12,729Apr 7, 2026

Full insider history for Alnylam Pharmaceuticals, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
ALNYLAM PHARMACEUTICALS, INC., CIK 1178670 on EDGAR
Extract generated
October 30, 2026
Withheld
none
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2013, income tax FY2021
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAmortizationAndAccretionNet, DepreciationDepletionAndAmortization
Share repurchases: not filed
Dividends paid: not filed

The data

The statements on this page as files, generated October 30, 2026.

JSON file
/data/financials/ALNY.json